Retatrutide Research Monograph

Receptor profile

Retatrutide engages three receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). The combined activity produces a downstream signalling profile distinct from dual agonists like tirzepatide and from GLP-1 mono-agonists like semaglutide.

Structure and half-life modification

The 39-amino-acid backbone carries a γGlu-C20 fatty-acid side chain for albumin binding and once-weekly research-dosing pharmacokinetics. Multiple aminoisobutyric acid substitutions and other non-canonical residues confer DPP-IV resistance.

Primary research literature

Retatrutide's foundational pharmacology papers run from 2022–2023. Phase 2 results published in 2023 (Jastreboff et al., NEJM) established its clinical pharmacology profile. The compound is currently in Phase 3 evaluation under the TRIUMPH program.

Distinguishing feature: glucagon receptor engagement

The glucagon receptor agonism component of retatrutide's profile is the defining mechanistic difference from tirzepatide. Glucagon receptor signalling contributes to hepatic and adipose-tissue effects that are not produced by selective GLP-1 or dual GLP-1/GIP engagement alone.

Storage, reconstitution, and handling

Lyophilised retatrutide is stable at −20°C in its sealed vial. After reconstitution, working solutions should be stored at 2–8°C and used within 14 days. Avoid repeated freeze-thaw cycles.

Quality and verification

VESPER retatrutide is supplied at ≥99.5% HPLC purity, with sequence identity confirmed by mass spectrometry on every batch.

Frequently asked